CHARLOTTESVILLE, Virginia and ATHENS, Greece, May 5, 2011 /PRNewswire/ — Biovista Inc. announced today that it’s EU affiliate has been awarded a prestigious grant worth $0.5 million, for research and development in the area of personalized medicine. The “p-medicine” project is a four-year, 13.3 million Euro co-funded effort under the European Community’s 7th Framework Programme … Read More
Author: Christos Andronis
The Scientist: Teaching an Old Drug New Tricks
Biotech companies hope to turn the practice of finding novel uses for existing compounds into big business. Andreas and Aris Persidis love to tackle big problems. As graduate students in the 1980s, the two brothers—a naval architect and a biochemist, respectively—would spend long nights knocking around ideas for how to engineer a better propeller or … Read More
Drug Repositioning podcast
Drug repositioning as a viable business strategy. Biovista’s President A. Persidis interview to GEN’s editor in chief, John Sterling. “Prompted by the need to refurbish their pipelines at lower costs and to drive and sustain future profits, drug companies have turned to drug repositioning, or repurposing, as a means of drug rediscovery. The process of … Read More
Biovista – a Dedicated Approach to Drug Repositioning
Seeking Alpha’s Jason Chew writes about Biovista’s Drug Repositioning approach: Following up my previous piece on drug repositioning by Orexigen with its diet pill, Contrave, I spoke with Dr. Aris Persidis, President and co-founder of Biovista- a leading company in the drug repositioning business. Drug repositioning is the discovery and development of novel indications for … Read More
Pfizer Seeks New Indications Using Biovista Bioinformatics
By Catherine Shaffer, BioWorld Today Contributing Writer A research collaboration between Pfizer Inc. and Biovista Inc. will seek new indications for Pfizer drug candidates in development using a bioinformatics technology platform developed by Biovista. Terms of the agreement include identification of up to three new indications for each drug. Biovista will receive an undisclosed up-front … Read More